Diarrhea

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day.

What is Diarrhea?

The term diarrhea (also spelled diarrhoea) refers to passage of loose, watery stools. The usual frequency of passing loose stools or watery stools in cases of diarrhea is at least three or more times a day.

Diarrhea Treatment

Stomach Cramps and Diarrhea: Distinguishing Between Common and Serious Causes

Diarrhea Symptoms

Diarrhea Causes

Diarrhea Prevention

Diarrhea Epidemiology

Diarrhea in Children

Acute Diarrhea

Chronic Diarrhea

Latest Diarrhea News and Research

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA Health reveals.

21 Nov 2024

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with mixed results from clinical trials.

19 Nov 2024

How vitamin B3 could be the secret to living longer and protecting your heart

Dietary niacin intake reduces risks of all-cause and cardiovascular mortality in US adults, with benefits more pronounced in non-diabetic individuals and linked to NAD metabolism improvements.

18 Nov 2024

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.

14 Nov 2024

Self-reported symptom screening reduces symptom burden in pediatric cancer patients

Regular, self-reported symptom screening was associated with reduced symptom burden when compared with usual care for pediatric patients with cancer, according to new research led by scientists at the University of Toronto and The Hospital for Sick Children (SickKids).

14 Nov 2024

Healthy low-carb diet and time-restricted eating improve weight loss and gut health beyond calorie restriction

Researchers discovered that a healthy low-carb diet and time-restricted eating, combined with moderate calorie restriction, offer significant weight loss and gut health benefits for overweight adults, with some effects lasting up to 28 weeks post-intervention.

13 Nov 2024

Novel bladder cancer treatment gains MHRA approval in the UK

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.

9 Nov 2024

New biomarker could predict response to IBD treatment

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

7 Nov 2024

Research sheds light on how fecal transplants improve gut health

In a novel study that identified male chromosome genetic material in the intestines of female patients undergoing fecal transplants, researchers at Johns Hopkins Medicine say they have significantly expanded scientific understanding of how some of these transplants may succeed and work.

6 Nov 2024

Binghamton University joins groundbreaking $42.8 million inflammatory disease treatment project

Binghamton University will play a key role in a federal grant of up to $42.8 million to develop an implantable device that acts as a living pharmacy to treat inflammatory diseases.

5 Nov 2024

Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

Researchers investigate the clinical efficacy of semaglutide in controlling urine albumin-to-creatinine ratio in overweight patients with chronic kidney disease.

31 Oct 2024

Ozempic effective for patients with chronic kidney damage

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic kidney disease and obesity.

28 Oct 2024

Targeted therapy and immunotherapy improve outcomes in rare thyroid cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.

24 Oct 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

New genetic variant may predict severe ulcerative colitis in patients

Abdominal pain, diarrhea, and debilitating fatigue define the daily lives of millions of people worldwide who suffer from chronic bowel disease.

17 Oct 2024

Novel app enables surveillance of global travel-related illness

On around one in three trips someone falls ill, with gastrointestinal and respiratory complaints among the most common symptoms.

15 Oct 2024

Dietitians boost GLP-1 therapy success with personalized care and side effect management

Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients on GLP-1 medications for weight management. The study highlights the critical role of dietitians in guiding lifestyle and dietary changes.

15 Oct 2024

Semaglutide improves heart health and reduces weight in obese patients, but with side effects

Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study highlights semaglutide's superiority over other GLP-1 agonists for cardiovascular health.

14 Oct 2024

Early signs of inflammatory bowel disease detected in newborns

Across the Western world, the prevalence of these chronic and serious conditions, which have no cure, is rising. In Denmark alone, 50,000 people suffer from either Crohn's disease or ulcerative colitis, which represents a doubling in cases over the past 20 years.

12 Oct 2024

UVA research reveals nervous system's role in C. difficile infections

The portion of our nervous systems responsible for the "fight or flight" response can shape the severity of potentially deadly C. difficile infections, new research from the University of Virginia School of Medicine reveals.

10 Oct 2024